Combination pharmacotherapy with reduced-dose fibrinolytic and platelet GP IIb/IIIa inhibition.
Combination fibrinolytic and antiplatelet therapy regimens may provide a means of inducing rapid reperfusion in patients requiring myocardial salvage after an acute myocardial infarction (AMI). This article describes case histories and a therapeutic regimen combining reteplase (5 U + 5 U double bolus) and abciximab (0.25 mg/kg bolus + 0.125 microg/kg/min infusion to a maximum of 10 microg/min for 12 h) for AMI patients before percutaneous coronary intervention (PCI). This medication regimen was used in the Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) V clinical trial, for the medical treatment of AMI, resulting in decreased reinfarction rates with similar mortality and intracranial hemorrhage rates as compared to standard fibrinolytic therapy.